UnitedHealth Group’s (UNH) Buy Rating Reiterated at Truist Financial

UnitedHealth Group (NYSE:UNH)‘s stock had its “buy” rating restated by Truist Financial in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $625.00 price target on the healthcare conglomerate’s stock, down from their prior price target of $640.00. Truist Financial’s price target points to a potential upside of 9.33% from the company’s current price.

UNH has been the topic of a number of other research reports. Argus upped their target price on shares of UnitedHealth Group from $570.00 to $600.00 and gave the company a “buy” rating in a research report on Wednesday, July 17th. Barclays raised their price target on shares of UnitedHealth Group from $560.00 to $604.00 and gave the company an “overweight” rating in a research report on Wednesday, July 17th. Wells Fargo & Company lifted their price target on shares of UnitedHealth Group from $525.00 to $630.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 17th. Morgan Stanley dropped their price objective on shares of UnitedHealth Group from $615.00 to $610.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, UBS Group lifted their price objective on shares of UnitedHealth Group from $640.00 to $680.00 and gave the company a “buy” rating in a research note on Thursday, July 18th. Two research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $616.74.

UnitedHealth Group Price Performance

Shares of UNH stock traded up $15.39 during trading hours on Wednesday, hitting $571.68. 2,418,485 shares of the company’s stock were exchanged, compared to its average volume of 3,946,349. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 0.67. The firm has a market cap of $526.17 billion, a P/E ratio of 34.99, a P/E/G ratio of 1.66 and a beta of 0.58. UnitedHealth Group has a fifty-two week low of $436.38 and a fifty-two week high of $608.63. The firm has a 50 day moving average of $584.11 and a two-hundred day moving average of $532.57.

UnitedHealth Group (NYSE:UNH) last issued its earnings results on Tuesday, October 15th. The healthcare conglomerate reported $7.15 EPS for the quarter, beating analysts’ consensus estimates of $7.00 by $0.15. UnitedHealth Group had a net margin of 3.66% and a return on equity of 26.55%. The business had revenue of $100.82 billion during the quarter, compared to analysts’ expectations of $99.14 billion. During the same period in the prior year, the business earned $6.56 earnings per share. The company’s quarterly revenue was up 9.2% compared to the same quarter last year. Sell-side analysts forecast that UnitedHealth Group will post 27.69 EPS for the current year.

Insider Activity at UnitedHealth Group

In related news, EVP Erin Mcsweeney sold 1,500 shares of the stock in a transaction that occurred on Thursday, July 18th. The stock was sold at an average price of $579.03, for a total transaction of $868,545.00. Following the completion of the sale, the executive vice president now directly owns 7,785 shares of the company’s stock, valued at approximately $4,507,748.55. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.33% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On UnitedHealth Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kathleen S. Wright Associates Inc. acquired a new stake in UnitedHealth Group in the third quarter worth $27,000. Macroview Investment Management LLC lifted its stake in shares of UnitedHealth Group by 671.4% in the second quarter. Macroview Investment Management LLC now owns 54 shares of the healthcare conglomerate’s stock valued at $28,000 after buying an additional 47 shares in the last quarter. Delos Wealth Advisors LLC lifted its position in shares of UnitedHealth Group by 757.1% during the first quarter. Delos Wealth Advisors LLC now owns 60 shares of the healthcare conglomerate’s stock valued at $30,000 after purchasing an additional 53 shares in the last quarter. Bbjs Financial Advisors LLC purchased a new stake in UnitedHealth Group during the second quarter worth about $31,000. Finally, Global Wealth Strategies & Associates increased its stake in shares of UnitedHealth Group by 152.4% in the third quarter. Global Wealth Strategies & Associates now owns 53 shares of the healthcare conglomerate’s stock worth $31,000 after purchasing an additional 32 shares in the last quarter. 87.86% of the stock is currently owned by institutional investors and hedge funds.

About UnitedHealth Group

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.